{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-033875","form_type":"8-K","ticker":"ARVN","cik":"0001655759","company_name":"ARVINAS, INC.","filed_at":"2026-05-12T11:15:37+00:00","discovered_at":"2026-05-12T11:20:00.282766+00:00","generated_at":"2026-05-12T11:21:36.463134+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":1.0,"calibrated_materiality_score":1.0,"confidence":"high","headline":"Arvinas reports Q1 2026; FDA approves first PROTAC VEPPANU; licenses to Rigel","bullets":["FDA approved VEPPANU (vepdegestrant) for ESR1m, ER+/HER2- advanced breast cancer — first PROTAC therapy approved.","Entered license agreement with Rigel Pharmaceuticals for exclusive global rights to VEPPANU; closing subject to HSR approval.","Cash and equivalents $614.9M at Mar 31, 2026 (Dec 31, 2025: $685.4M); cash runway into 2H 2028.","Randy Teel appointed President, CEO, and Director; Briggs Morrison elected Chair of the Board.","ARV-102 Phase 1: >50% LRRK2 degradation in CSF; ARV-806 KRAS G12D dose escalation complete; ARV-027 Phase 1 initiated."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-033875","json":"https://secwatch.observer/filing/0001628280-26-033875.json","markdown":"https://secwatch.observer/filing/0001628280-26-033875.md","text":"https://secwatch.observer/filing/0001628280-26-033875.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1655759/000162828026033875/0001628280-26-033875-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1655759/000162828026033875/arvn-20260512.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-12T11:21:36.463134+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"96311dc046f75f073464f2db81271bc3cbb146d0","claim":"ARVINAS, INC. reported financial results for first quarter 2026.","evidence_excerpt":"On May 12, 2026, Arvinas, Inc. (the \"Company\") announced its financial results for the quarter ended March 31, 2026 and provided a corporate update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1655759/000162828026033875/0001628280-26-033875-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter 2026"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}